CD36 and neoplasm: Although ABT-510 does not significantly inhibit fatty acid uptake [251], future TSP1-derived therapeutic agents that potently inhibit CD36 fatty acid transport could enhance anti-tumor immunity and improve T cell-targeted combination therapies.